Tacalyx raises €7 million in seed funding to generate first-in-class anti-TACA antibodies for cancer treatment
The Max Planck spin-out launches with a syndicate co-led by Boehringer Ingelheim Venture Fund and Kurma Partners.
Tacalyx, a spin-out of the Max Planck Institute of Colloids and Interfaces, has secured €7 million in seed funding. The round was co-led by Boehringer Ingelheim Venture Fund and Kurma Partners, joined by Idinvest Partners, High-Tech Gründerfonds, coparion and Creathor Ventures.
Tacalyx holds licenses from Max-Planck-Innovation to the technology and discoveries of its scientific co-founders, Prof. Dr. Peter H. Seeberger and Dr. Oren Moscovitz. The company combines the ability to synthesize ultra-pure, highly complex TACA structures with the screening capabilities and experience needed to generate antibodies against non-peptidic targets.
